New antibody cocktail aims to block HIV without daily pills

NCT ID NCT07390955

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing whether lab-made antibodies that target HIV are safe and how long they stay in the body. About 83 healthy adults without HIV will receive the antibodies by vein or under the skin, alone or in combination. The goal is to find the right dose and check for side effects, not to treat HIV yet.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

lab-made antibodies (ePGT121v1-LS, PGDM1400LS, VRC07-523LS)

What this could lead to

If successful, this could point toward a new way to control HIV without daily pills, using periodic antibody infusions or shots.

What could go wrong

This is a very early Phase 1 safety study with only 83 healthy volunteers, not people with HIV. It is too soon to know if the antibodies will work against the virus in real-world conditions.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Alabama CRS (Site ID: 31788)

    RECRUITING

    Birmingham, Alabama, 35222, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Bridge HIV CRS (Site ID: 30305)

    RECRUITING

    San Francisco, California, 94102, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Brigham and Women's Hospital Vaccine CRS (BWH VCRS) (Site ID: 30007)

    NOT_YET_RECRUITING

    Boston, Massachusetts, 02115, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Centro de Investigaciones Tecnológicas, Biomédicas y Medioambientales CRS (CITBM) - Unidad de Ensayos Clínicos (UNIDEC) (Site ID: 31970)

    NOT_YET_RECRUITING

    Bellavista, Provincia Constitucional del Callao, 07006, Peru

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • George Washington University CRS (Site ID: 31608)

    NOT_YET_RECRUITING

    Washington D.C., District of Columbia, 20052, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Houston Advancing Research Team CRS (Site ID: 31473)

    NOT_YET_RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Penn Prevention CRS (Site ID: 30310)

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Seke South CRS (Site ID: 30294)

    NOT_YET_RECRUITING

    Harare, Zimbabwe

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Spilhaus CRS (Site ID: 30314)

    NOT_YET_RECRUITING

    Harare, Zimbabwe

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Ponce de Leon Center CRS (Site ID: 5802)

    NOT_YET_RECRUITING

    Atlanta, Georgia, 30308, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Vanderbilt Vaccine (VV) CRS (Site ID: 30352)

    RECRUITING

    Nashville, Tennessee, 37232, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Via Libre CRS (Site ID: 31909)

    NOT_YET_RECRUITING

    Lima Cercado, Lima region, 15001, Peru

    Contact Phone: •••-•••-•••• Email: •••••@•••••